Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
59 hedge funds and large institutions have $81.7M invested in Cidara Therapeutics in 2018 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 19 increasing their positions, 11 reducing their positions, and 5 closing their positions.
73% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 11
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
5% more funds holding
Funds holding: 56 → 59 (+3)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.09% less ownership
Funds ownership: 3.36% → 3.27% (-0.09%)
18% less capital invested
Capital invested by funds: $99.1M → $81.7M (-$17.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Alethea Capital Management
Mercer Island,
Washington
|
+$1.45M |
| 2 |
FI
Fosun International
Hong Kong,
China
|
+$1.35M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$1.02M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$379K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$375K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
-$3.68M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.52M |
| 3 |
Millennium Management
New York
|
-$1.26M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$481K |
| 5 |
Invesco
Atlanta,
Georgia
|
-$291K |
CDTX Hedge Fund Activity: Q3 2018 in Review
59 of the 4,390 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q3 2018, worth a combined $81.7M — down 18% from $99.1M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CDTX positions and 5 closed out — a net gain of 3 holders — while 19 added to existing stakes and 11 trimmed.
The largest buyer was Alethea Capital Management, adding an estimated $1.45M. The largest seller was Prosight Management, cutting an estimated $3.68M.
- 59 institutional investors held Cidara Therapeutics (CDTX) as of Q3 2018, up from 56 in Q2 2018.
- Funds reported $81.7M of Cidara Therapeutics stock for Q3 2018, down 18% quarter-over-quarter.
- 8 funds opened new Cidara Therapeutics positions in Q3 2018 and 5 closed out, a net change of +3 holders.
- The largest Cidara Therapeutics buyer in Q3 2018 was Alethea Capital Management, an estimated $1.45M added.
- The largest Cidara Therapeutics seller in Q3 2018 was Prosight Management, an estimated $3.68M sold.
Based on aggregated 13F filings for Q3 2018.